Developer docs
API playgroundTry for free, no card

Search company profiles

Xinvento

Full company profile

uuid000a97y

Namestring
Xinvento
Websiteurl
xinvento.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Xinvento is an early-stage biotechnology company founded in 2021 and headquartered in Amsterdam, Netherlands. The company is focused on developing a treatment for Congenital Hyperinsulinism (CHI), a rare disease that primarily affects children and for which current effective therapeutic options are limited. Its core technology consists of designing and testing proprietary molecules intended to serve as drug candidates for CHI patients, with the stated goal of identifying viable candidates within roughly one year of seed funding.

The company operates in a pre-clinical, pre-revenue drug discovery phase. As of the available data, Xinvento has not disclosed any commercial products, pricing models, marketing or distribution channels, partnerships, or named customers. The company's public web presence (xinvento.com) is a parked domain registered with Hostnet, a Dutch hosting provider, indicating no active commercial-facing web operations. No management team, board, scientific advisory board, institutional investors, patents, or regulatory milestones have been publicly disclosed. The firm operates with a headcount of 1–10 employees.

Xinvento's business model is conventional for a pre-clinical biotech: it raises external capital to fund R&D aimed at producing a viable drug candidate, after which commercialization pathways (out-licensing, partnership, or independent development) would be evaluated. To date, the company has completed one seed funding round in April 2022, the amount of which was not publicly disclosed. There is no current revenue, no pricing model, and no articulated path to market. The company is privately held, with no parent company or disclosed ownership structure beyond founders.

Short descriptiontext

Xinvento is a privately held, pre-clinical biotech company founded in 2021 in Amsterdam, Netherlands. It develops proprietary small-molecule drug candidates aimed at treating Congenital Hyperinsulinism (CHI), a rare pediatric disease with limited therapeutic options.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAmsterdam, Netherlands
HQ citystring
Amsterdam
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
rare disease therapeutics, congenital hyperinsulinism treatment, proprietary molecule development, preclinical drug discovery, orphan disease research
Industry1 code
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Rare Disease Therapeutics
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Xinvento is developing proprietary molecules aimed at producing drug candidates to treat Congenital Hyperinsulinism (CHI), a rare disease with limited therapeutic options. The company is in the preclinical discovery stage, having completed a seed funding round intended to identify drug candidates within one year.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Goal to identify drug candidates within one year of seed funding
Product overview1 text field

Xinvento is an early-stage biotech company founded in 2021 that is focused on developing a treatment for Congenital Hyperinsulinism (CHI). The company completed a seed funding round to support the design and testing of proprietary molecules to identify drug candidates within a year. No specific named products or services were identified in the available source data.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Sobi is a European-headquartered rare disease specialty pharma with strong presence in rare pediatric and metabolic disorders. Relevant comparator given Xinvento's Netherlands location and rare pediatric focus.

TypeEmerging player
Description

Crinetics focuses on rare endocrine diseases with a small-molecule discovery platform. Comparable to Xinvento in rare endocrine target space and small-molecule R&D approach, though it covers broader indications.

3Tiburio Therapeutics
TypeEmerging player
Description

Tiburio is a clinical-stage rare endocrine disease biotech. Comparable as a small rare-disease company with similar stage profile and a focus on underserved endocrine indications.

TypeEmerging player
Description

Eiger is a clinical-stage rare disease biotech with multiple rare disease programs. Comparable as a small rare-disease focused development-stage company pursuing orphan indications.

TypeBroad incumbent
Description

Ultragenyx is a commercial-stage rare disease company with established rare pediatric franchises. Comparable market (rare pediatric disease) and overlapping therapeutic targets, but considerably larger and broader in scope.

TypeBroad incumbent
Description

BioMarin is a leading rare disease biotech with multiple approved rare pediatric therapies. Operates in the same orphan/rare pediatric disease commercial space Xinvento targets, with deep regulatory and commercial infrastructure.

TypeDirect peer
Description

Rezolute is developing RZ358, an anti-insulin receptor antibody for congenital hyperinsulinism — the same indication as Xinvento's program. Most directly comparable peer given identical therapeutic focus on CHI.

TypeDirect peer
Description

Soleno is advancing diazoxide choline (DCCR) for hyperinsulinism, including congenital forms. Directly comparable to Xinvento as a clinical-stage rare disease company targeting hyperinsulinemic disorders.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Xinvento

Rare Disease Therapeuticsxinvento.com

Xinvento is a privately held, pre-clinical biotech company founded in 2021 in Amsterdam, Netherlands. It develops proprietary small-molecule drug candidates aimed at treating Congenital Hyperinsulinism (CHI), a rare pediatric disease with limited therapeutic options.

What Xinvento does

Xinvento is an early-stage biotechnology company founded in 2021 and headquartered in Amsterdam, Netherlands. The company is focused on developing a treatment for Congenital Hyperinsulinism (CHI), a rare disease that primarily affects children and for which current effective therapeutic options are limited. Its core technology consists of designing and testing proprietary molecules intended to serve as drug candidates for CHI patients, with the stated goal of identifying viable candidates within roughly one year of seed funding.

The company operates in a pre-clinical, pre-revenue drug discovery phase. As of the available data, Xinvento has not disclosed any commercial products, pricing models, marketing or distribution channels, partnerships, or named customers. The company's public web presence (xinvento.com) is a parked domain registered with Hostnet, a Dutch hosting provider, indicating no active commercial-facing web operations. No management team, board, scientific advisory board, institutional investors, patents, or regulatory milestones have been publicly disclosed. The firm operates with a headcount of 1–10 employees.

Xinvento's business model is conventional for a pre-clinical biotech: it raises external capital to fund R&D aimed at producing a viable drug candidate, after which commercialization pathways (out-licensing, partnership, or independent development) would be evaluated. To date, the company has completed one seed funding round in April 2022, the amount of which was not publicly disclosed. There is no current revenue, no pricing model, and no articulated path to market. The company is privately held, with no parent company or disclosed ownership structure beyond founders.

Xinvento firmographics

Firmographics
Name
Xinvento
Website
https://xinvento.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Xinvento is a privately held, pre-clinical biotech company founded in 2021 in Amsterdam, Netherlands. It develops proprietary small-molecule drug candidates aimed at treating Congenital Hyperinsulinism (CHI), a rare pediatric disease with limited therapeutic options.
Ownership category
akta.pro rank

Xinvento industry classification

Industry
Product category
Rare Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Congenital hyperinsulinism treatment
  • Proprietary molecule development
  • Preclinical drug discovery
  • Orphan disease research

Where Xinvento is headquartered

Location

Headquarters

HQ city
Amsterdam
HQ country
Netherlands
HQ region
Europe

Markets served

Xinvento business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Xinvento product offering

Product offering

Core offering

Xinvento is developing proprietary molecules aimed at producing drug candidates to treat Congenital Hyperinsulinism (CHI), a rare disease with limited therapeutic options. The company is in the preclinical discovery stage, having completed a seed funding round intended to identify drug candidates within one year.

Product overview

Xinvento is an early-stage biotech company founded in 2021 that is focused on developing a treatment for Congenital Hyperinsulinism (CHI). The company completed a seed funding round to support the design and testing of proprietary molecules to identify drug candidates within a year. No specific named products or services were identified in the available source data.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Goal to identify drug candidates within one year of seed funding

Companies that use Xinvento

Customer profile

Segments1 record

Ideal customer profiles1 record

Xinvento technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Xinvento partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves2 records

Expansion highlights2 records

Xinvento competitors and assessment

Company assessment

Broad incumbents

  • Swedish Orphan Biovitrum (Sobi): Sobi is a European-headquartered rare disease specialty pharma with strong presence in rare pediatric and metabolic disorders. Relevant comparator given Xinvento's Netherlands location and rare pediatric focus.
  • Ultragenyx Pharmaceutical: Ultragenyx is a commercial-stage rare disease company with established rare pediatric franchises. Comparable market (rare pediatric disease) and overlapping therapeutic targets, but considerably larger and broader in scope.
  • BioMarin Pharmaceutical: BioMarin is a leading rare disease biotech with multiple approved rare pediatric therapies. Operates in the same orphan/rare pediatric disease commercial space Xinvento targets, with deep regulatory and commercial infrastructure.

Emerging players

  • Crinetics Pharmaceuticals: Crinetics focuses on rare endocrine diseases with a small-molecule discovery platform. Comparable to Xinvento in rare endocrine target space and small-molecule R&D approach, though it covers broader indications.
  • Tiburio Therapeutics: Tiburio is a clinical-stage rare endocrine disease biotech. Comparable as a small rare-disease company with similar stage profile and a focus on underserved endocrine indications.
  • Eiger BioPharmaceuticals: Eiger is a clinical-stage rare disease biotech with multiple rare disease programs. Comparable as a small rare-disease focused development-stage company pursuing orphan indications.

Direct peers

  • Rezolute: Rezolute is developing RZ358, an anti-insulin receptor antibody for congenital hyperinsulinism — the same indication as Xinvento's program. Most directly comparable peer given identical therapeutic focus on CHI.
  • Soleno Therapeutics: Soleno is advancing diazoxide choline (DCCR) for hyperinsulinism, including congenital forms. Directly comparable to Xinvento as a clinical-stage rare disease company targeting hyperinsulinemic disorders.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Xinvento social profiles

Digital presence

Xinvento financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Xinvento leadership team

Management profile

Number of profiles

Xinvento funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Xinvento M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xinvento

What does Xinvento do?

Xinvento is developing proprietary molecules aimed at producing drug candidates to treat Congenital Hyperinsulinism (CHI), a rare disease with limited therapeutic options. The company is in the preclinical discovery stage, having completed a seed funding round intended to identify drug candidates within one year.

Is Xinvento a public or private company?

Xinvento is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Xinvento founded?

Xinvento was founded in 2021. It employs 1 to 10 people.

Where is Xinvento based?

Xinvento is headquartered in Amsterdam, Netherlands, in the Europe region.

Who are Xinvento's main competitors?

Broad incumbents on record are Swedish Orphan Biovitrum (Sobi), Ultragenyx Pharmaceutical and BioMarin Pharmaceutical. Emerging players are Crinetics Pharmaceuticals, Tiburio Therapeutics and Eiger BioPharmaceuticals. Direct peers are Rezolute and Soleno Therapeutics.

Does Xinvento have an API?

No public API is recorded for Xinvento.

What industry is Xinvento in?

Xinvento's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Silicon CanalsRhythm Pharmaceuticals BV acquires Amsterdam’s Xinvento to develop therapies for congenital hyperinsulinismRhythm Pharmaceuticals Netherlands BV acquired Amsterdam-based Xinvento BV for an initial $5 million, with potential milestone payments reaching up to $211 million. The acquisition aims to expand Rhythm's pipeline into congenital hyperinsulinism (CHI), a rare genetic condition, leveraging Xinvento’s investigational therapeutic candidates. Xinvento founder Claudine van der Sande will join Rhythm as vice president and head of the CHI programme.GlobeNewswireRhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational TherapeuticsRhythm Pharmaceuticals acquired Xinvento B.V., a biotech developing therapies for congenital hyperinsulinism, for $5 million upfront plus up to $150 million in milestones. The deal expands Rhythm's rare endocrinology pipeline, with clinical development expected in 2024.The Pharma LetterRhythm expands into related genetic disease with Xinvento buyoutRhythm Pharmaceuticals has acquired Xinvento, a Netherlands-based biotech company specializing in therapies for congenital hyperinsulinism. This acquisition marks Rhythm's expansion into related genetic diseases beyond its current portfolio.GlobeNewswireRhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational TherapeuticsRhythm Pharmaceuticals, Inc. announced the acquisition of Xinvento B.V., a biotech company focused on therapies for congenital hyperinsulinism. The acquisition is expected to enhance Rhythm's pipeline with clinical development to begin in 2024, involving an initial payment of $5 million and potential further milestones totaling up to $206 million. This move aligns with Rhythm's strategic focus on rare endocrinology diseases.RhythmtxRhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics – Rhythm Pharmaceuticals, Inc.Rhythm Pharmaceuticals acquired Xinvento B.V. and its portfolio of investigational therapeutics for congenital hyperinsulinism, paying an upfront fee of $5 million with potential milestone payments totaling up to $211 million. The acquisition aligns with Rhythm’s strategy in rare endocrinology diseases, and the company expects to initiate clinical development of the new therapeutic candidate in 2024.FinSMEsXinvento Raises Seed FundingXinvento, an Amsterdam-based biotech, raised an undisclosed seed round from backers including Ed Kaye and John Maraganore. The funds will design and test proprietary molecules in pre-clinical models to identify drug candidates for Congenital Hyperinsulinism, a rare disease causing severe hypoglycemia in newborns and children.GlobeNewswireDutch biotech Xinvento raises seed round to develop a treatment for the rare disease Congenital HyperinsulinismXinvento, a biotech targeting Congenital Hyperinsulinism, completed a seed funding round. The funds will support preclinical testing of proprietary molecules to identify drug candidates. The company expects to deliver clinical candidate molecules within one year.BioSpaceDutch biotech Xinvento raises seed round to develop a treatment for the rare disease Congenital HyperinsulinismDutch biotech company Xinvento has completed a seed funding round to develop treatments for Congenital Hyperinsulinism, a rare disease characterized by severe hypoglycemia. The company plans to use the funds to design and test proprietary molecules in pre-clinical models with the goal of identifying potential drug candidates within one year.GlobeNewswireDutch biotech Xinvento raises seed round to develop a treatment for the rare disease Congenital HyperinsulinismDutch biotech company Xinvento has completed a seed funding round to develop treatments for Congenital Hyperinsulinism, a rare disease causing severe hypoglycemia in children. The funding is backed by seasoned industry leaders and will support the design and testing of proprietary molecules to identify potential drug candidates within the next year.